Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies

[1]  C. Hudis,et al.  Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.

[2]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[4]  R. Hoffman,et al.  Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. , 1998, Protein expression and purification.

[5]  K. Maruyama,et al.  Immunoliposomes bearing polyethyleneglycol‐coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo , 1997, FEBS letters.

[6]  J. Chern,et al.  Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs , 1997, Cancer Immunology, Immunotherapy.

[7]  S. Hilsenbeck,et al.  Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. , 1997, European journal of cancer.

[8]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[9]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[10]  Y. Tsutsumi,et al.  Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. , 1996, The Journal of pharmacology and experimental therapeutics.

[11]  P. Ghosh,et al.  A colorimetric assay for estimation of polyethylene glycol and polyethylene glycolated protein using ammonium ferrothiocyanate. , 1996, Analytical biochemistry.

[12]  R. Melton,et al.  Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. , 1996, British Journal of Cancer.

[13]  F. Marincola,et al.  The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma , 1995, Cancer.

[14]  Y. Tsutsumi,et al.  Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. , 1995, British Journal of Cancer.

[15]  Y. Yarden,et al.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Voûte,et al.  An open‐label, multicenter study of polyethylene glycol‐L‐asparaginase for the treatment of acute lymphoblastic leukemia , 1995, Cancer.

[17]  P. D. De Mulder,et al.  PEG‐IL‐2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclopphosphamide , 1994, International journal of cancer.

[18]  Y. Inada,et al.  Stabilization of L-asparaginase modified with comb-shaped poly(ethylene glycol) derivatives, in vivo and in vitro. , 1994, Bioconjugate chemistry.

[19]  I. Pastan,et al.  Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. , 1994, The Journal of biological chemistry.

[20]  N. Kusunose,et al.  Antimetastatic Activity of Polymeric RGDT Peptides Conjugated with Poly(ethylene glycol) , 1993, Japanese journal of cancer research : Gann.

[21]  T. Berg,et al.  Uptake, intracellular transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes. , 1992, The Journal of biological chemistry.

[22]  S. Rosenberg,et al.  Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer. , 1991, Lymphokine and cytokine research.

[23]  A. Ullrich,et al.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Yamaguchi,et al.  Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. , 1991, Cancer research.

[25]  T. Yamaguchi,et al.  Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. , 1990, Biochemical and biophysical research communications.

[26]  L V Rubinstein,et al.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. , 1990, Journal of the National Cancer Institute.

[27]  M. Sela,et al.  Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.

[28]  M. McKinney,et al.  A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. , 1987, Journal of immunological methods.

[29]  C. Verhoest,et al.  Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. , 1984, Cancer biochemistry biophysics.

[30]  M. Wilchek,et al.  The effect in vivo of chemotherapeutic drug—antibody conjugates in two murine experimental tumor systems , 1978, International journal of cancer.

[31]  S. Snyder,et al.  An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. , 1975, Analytical biochemistry.

[32]  P. Caliceti,et al.  A branched monomethoxypoly(ethylene glycol) for protein modification. , 1995, Bioconjugate chemistry.

[33]  高階 謙一郎.  Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol , 1994 .